Letter | Published:

MX2 is an interferon-induced inhibitor of HIV-1 infection

Nature volume 502, pages 563566 (24 October 2013) | Download Citation

Abstract

HIV-1 replication can be inhibited by type I interferon (IFN), and the expression of a number of gene products with anti-HIV-1 activity is induced by type I IFN1,2. However, none of the known antiretroviral proteins can account for the ability of type I IFN to inhibit early, preintegration phases of the HIV-1 replication cycle in human cells3,4. Here, by comparing gene expression profiles in cell lines that differ in their ability to support the inhibitory action of IFN-α at early steps of the HIV-1 replication cycle, we identify myxovirus resistance 2 (MX2) as an interferon-induced inhibitor of HIV-1 infection. Expression of MX2 reduces permissiveness to a variety of lentiviruses, whereas depletion of MX2 using RNA interference reduces the anti-HIV-1 potency of IFN-α. HIV-1 reverse transcription proceeds normally in MX2-expressing cells, but 2-long terminal repeat circular forms of HIV-1 DNA are less abundant, suggesting that MX2 inhibits HIV-1 nuclear import, or destabilizes nuclear HIV-1 DNA. Consistent with this notion, mutations in the HIV-1 capsid protein that are known, or suspected, to alter the nuclear import pathways used by HIV-1 confer resistance to MX2, whereas preventing cell division increases MX2 potency. Overall, these findings indicate that MX2 is an effector of the anti-HIV-1 activity of type-I IFN, and suggest that MX2 inhibits HIV-1 infection by inhibiting capsid-dependent nuclear import of subviral complexes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 325, 602–604 (1985)

  2. 2.

    & Human immunodeficiency virus, restriction factors, and interferon. J. Interferon Cytokine Res. 29, 569–580 (2009)

  3. 3.

    , , & Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. J. Virol. 87, 3549–3560 (2013)

  4. 4.

    et al. Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology 10, 23 (2013)

  5. 5.

    , , & Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002)

  6. 6.

    , & Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430 (2008)

  7. 7.

    , & Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812–818 (2007)

  8. 8.

    et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481–485 (2011)

  9. 9.

    et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848–853 (2004)

  10. 10.

    et al. Human MxB protein, an interferon-α-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J. Biol. Chem. 271, 23478–23486 (1996)

  11. 11.

    , & Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB. Proc. Natl Acad. Sci. USA 101, 8957–8962 (2004)

  12. 12.

    & Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J. Virol. 84, 9254–9266 (2010)

  13. 13.

    , , & Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog. 3, e156 (2007)

  14. 14.

    & Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78, 5670–5678 (2004)

  15. 15.

    & Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J. Virol. 80, 3712–3720 (2006)

  16. 16.

    et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7, 221–233 (2010)

  17. 17.

    et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 7, e1002439 (2011)

  18. 18.

    et al. Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. J. Virol. 87, 648–658 (2013)

  19. 19.

    et al. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 9, e1003461 (2013)

  20. 20.

    , & Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78, 12800–12808 (2004)

  21. 21.

    Fv1, the mouse retrovirus resistance gene. Rev. Sci. Tech. 17, 269–277 (1998)

  22. 22.

    & Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J. Virol. 83, 9835–9843 (2009)

  23. 23.

    et al. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 10, 20 (2013)

  24. 24.

    et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8, 1665–1668 (2001)

  25. 25.

    , , , & Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78, 6005–6012 (2004)

  26. 26.

    , , , & Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22, 385–394 (2003)

  27. 27.

    et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808–1818 (1999)

  28. 28.

    , & Mapping the encapsidation determinants of feline immunodeficiency virus. J. Virol. 76, 11889–11903 (2002)

  29. 29.

    et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 86, 2715–2728 (2012)

  30. 30.

    et al. Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol. 4, e435 (2006)

Download references

Acknowledgements

We thank members of The Rockefeller University Genomics Resource Center for assistance with the microarray experiments and members of the Bieniasz laboratory for discussion and advice. This work was supported by grants from the National Institutes of Health; R37AI64003 (to P.D.B.), R01AI078788 (to T.H.) R01AI100720 (to M.Y.), AI091707 to C.M.R., AI057158 (to I. Lipkin, Northeast Biodefense Center, subcontracted to C.M.R.) and DK095031 to J.W.S., the Greenberg Medical Research Institute and the Starr Foundation (C.M.R.) and by the Howard Hughes Medical Institute.

Author information

Author notes

    • Shalini S. Yadav
    • , Sam J. Wilson
    •  & John W. Schoggins

    Present addresses: University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9048, USA (J.W.S.); MRC Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK (S.J.W.); Weill Cornell Medical College, 525 East 68th street, New York, New York 10025, USA (S.S.Y.).

Affiliations

  1. Aaron Diamond AIDS Research Center, New York, New York 10016, USA

    • Melissa Kane
    • , Shalini S. Yadav
    • , Julia Bitzegeio
    • , Sebla B. Kutluay
    • , Trinity Zang
    • , Sam J. Wilson
    • , Masahiro Yamashita
    • , Theodora Hatziioannou
    •  & Paul D. Bieniasz
  2. Laboratory of Retrovirology, The Rockefeller University, New York, New York 10065, USA

    • Melissa Kane
    • , Shalini S. Yadav
    • , Julia Bitzegeio
    • , Sebla B. Kutluay
    • , Trinity Zang
    • , Sam J. Wilson
    •  & Paul D. Bieniasz
  3. Howard Hughes Medical Institute, New York, New York 10016, USA

    • Shalini S. Yadav
    • , Trinity Zang
    • , Sam J. Wilson
    •  & Paul D. Bieniasz
  4. Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10065, USA

    • John W. Schoggins
    •  & Charles M. Rice

Authors

  1. Search for Melissa Kane in:

  2. Search for Shalini S. Yadav in:

  3. Search for Julia Bitzegeio in:

  4. Search for Sebla B. Kutluay in:

  5. Search for Trinity Zang in:

  6. Search for Sam J. Wilson in:

  7. Search for John W. Schoggins in:

  8. Search for Charles M. Rice in:

  9. Search for Masahiro Yamashita in:

  10. Search for Theodora Hatziioannou in:

  11. Search for Paul D. Bieniasz in:

Contributions

M.K., S.S.Y., J.B., S.B.K., T.Z. and S.J.W. designed and executed the experiments and analysed the data. J.W.S. and C.M.R. provided an interferon-stimulated gene library and advice. M.Y. provided reagents and advice. T.H. provided reagents and advice and supervised the work. P.D.B. conceived the study, supervised the work and wrote the paper, with additional input from all authors.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Paul D. Bieniasz.

Extended data

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature12653

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.